BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 14, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Apoptone: Phase I/IIa completed

Harbor completed an open-label, U.S. Phase I/IIa trial evaluating 10-700 mg/day Apoptone in 68 patients. Last September, Harbor reported data from 22 chemotherapy-naïve patients showing that 100 or 350 mg/day Apoptone produced 20 cases...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >